Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Dongwen Lv(The University of Texas Health Science Center at San Antonio), Daohong Zhou(The University of Texas at San Antonio Health Science Center)

Nature Communications

November 25, 2021

10.1038/s41467-021-27210-x

Cited by 145

Related Papers

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

|Journal of Hematology & Oncology|2020|129

Piperlongumine conjugates induce targeted protein degradation

|Cell chemical biology|2023|70

Senescence-associated hyper-activation to inflammatory stimuli in vitro

|Aging|2021|57

Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice

|Cell Death Discovery|2023|43

A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice

|Nature Aging|2025|37